España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
iShares Biotechnology ETF
IBB
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$136.29
0.19
0.14%
At close: -
$136.29
0.00
0.00%
After Hours: 4:05 PM EDT
Get Report
Comment
Overview
News
Holdings
Dividends
Short Interest
Latest news for iShares Biotechnology ETF (NASDAQ:IBB)
iShares Biotechnology ETF (NASDAQ: IBB)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, January 09, 2025
Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ
Rishabh Mishra
Monday, November 18, 2024
Cameco, Applied Digital, West Pharmaceutical And More On CNBC's 'Final Trades'
Avi Kapoor
Thursday, November 14, 2024
Elliott Investment Management 13F Shows Exite...
Benzinga Newsdesk
Wednesday, July 31, 2024
Should You Invest in the iShares Biotechnology ETF?
Zacks
Monday, July 01, 2024
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
Piero Cingari
Friday, June 21, 2024
Stocks Stall As Chip Sector Struggles To Rebound; Dollar Eyes 7-Week Peak, Gold, Bitcoin Retreat: What's Driving Markets Friday?
Piero Cingari
Tuesday, April 30, 2024
April Showers On Wall Street: Miners, Utilities Emerge As Bright Spots In Gloomy Market
Piero Cingari
Monday, January 29, 2024
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
Neil Dennis
Friday, January 05, 2024
Live On CNBC, Jason Snipe's Contrarian Idea: ...
Benzinga Newsdesk
Wednesday, January 03, 2024
US Stocks Eye 3-Day Slump; Tech, Crypto Sell-Off Deepens, Oil, Dollar Rebound: What's Driving Markets Wednesday?
Piero Cingari
Tuesday, January 02, 2024
Tech Drags On Wall Street As 2024 Kicks Off; Dollar and Treasury Yields Surge: What's Driving Markets Tuesday?
Piero Cingari
Friday, December 29, 2023
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback
Surbhi Jain
Tuesday, December 26, 2023
Wall Street Sees Post-Holiday Gains, Oil Rallies, Intel Leads: What's Driving Markets Tuesday?
Piero Cingari
Friday, December 22, 2023
S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday?
Piero Cingari
Thursday, December 21, 2023
US Stocks Bounce; Chipmakers, Cruise Lines Lead, Dollar Falls: What's Driving Markets Thursday?
Piero Cingari
Wednesday, December 20, 2023
Wall Street Edges Higher, Small Caps Eye Best Month In 3 Years, Bitcoin Rebounds: What's Driving Markets Wednesday?
Piero Cingari
Tuesday, November 07, 2023
Activist Investor Elliott Pushes for Strategy Revamp at BioMarin Amid CEO Change
Vandana Singh
Thursday, August 31, 2023
Industry ETFs In The Spotlight: August's Winners And Losers Revealed: Where Is Gold, Energy And Biotech?
Piero Cingari
Saturday, August 12, 2023
Weight-Loss Drug Wegovy Adds Mass To Novo Nordisk's stock, Pushing Valuation Past Denmark's GDP
Shanthi Rexaline
Thursday, August 10, 2023
Disinflation Talk Grows, Rate Hike Bets Plummet: Top 5 ETFs Rallying On CPI Miss
Piero Cingari
Monday, July 31, 2023
Rising Stars, Falling Trends: July's Industry ETF Winners And Losers
Piero Cingari
Thursday, April 13, 2023
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
Vandana Singh
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
Vandana Singh
Wednesday, April 12, 2023
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
Vandana Singh
Tuesday, April 11, 2023
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
Vandana Singh
Thursday, April 06, 2023
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
Vandana Singh
AbbVie, Thermo Fisher Scientific And A Must-Watch Biotech ETF: CNBC's 'Final Trades'
Lisa Levin
Thursday, March 16, 2023
US Judge Weighs Nationwide Ban On Abortion Pills
Vandana Singh
Monday, March 13, 2023
Silicon Valley Bank Meltdown Hits Healthcare Sector As Well
Vandana Singh
Friday, March 10, 2023
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
Vandana Singh
FDA Seeks 10% Increase In Biden's FY 2024 Budget, Proposes Enhancing Regulatory Authorities
Vandana Singh
Wednesday, March 08, 2023
Covis Pharma To Withdraw Only FDA-Approved Treatment To Prevent Preterm Births
Vandana Singh
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Vandana Singh
Wednesday, March 01, 2023
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
Vandana Singh
Monday, February 20, 2023
Man in Germany Cured of HIV After Undergoing Stem Cell Transplant, According to Report in Nature Medicine
Charles Gross
Tuesday, January 31, 2023
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Shanthi Rexaline
Friday, January 06, 2023
Longeveron Shares Surge Following FDA Decisio...
Benzinga Newsdesk
SAVA, LLY, IBB: Why These Alzheimer's Related...
Benzinga Newsdesk
Tuesday, December 27, 2022
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Shanthi Rexaline
Monday, December 05, 2022
Meta Platforms, This Biotech ETF And These China Plays Are CNBC's 'Final Trades'
Priya Nigam
Friday, December 02, 2022
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Shanthi Rexaline
Thursday, December 01, 2022
BriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
Faith Ashmore
-
Sponsored
Tuesday, November 01, 2022
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
Shanthi Rexaline
Thursday, October 27, 2022
These 4 ETFs Feature on CNBC's 'Final Trades'
Priya Nigam
Sunday, October 02, 2022
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Shanthi Rexaline
Wednesday, August 31, 2022
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
Shanthi Rexaline
Wednesday, August 10, 2022
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Vandana Singh
Tuesday, August 09, 2022
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Vandana Singh
Friday, August 05, 2022
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Vandana Singh
Thursday, August 04, 2022
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Vandana Singh
Show More
